Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Stock
NASDAQ · RYTM
95.68
Fundamentals
Market cap
$6.79B
Price / Earnings ratio
-32.2x
Price / Sales ratio
28.2x
Price / Book ratio
65.7x
Return on assets
-46.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

The Motley Fool
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
NeutralRYTMAugust 23, 2026
The Motley FoolNeutral
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
RYTM

MarketBeat
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
NeutralRYTMAugust 17, 2026
MarketBeatNeutral
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
RYTM

MarketBeat
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
NeutralRYTMAugust 4, 2026
MarketBeatNeutral
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
RYTM

Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
NeutralRYTMAugust 4, 2026
Zacks Investment ResearchNeutral
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
RYTM
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral1
Buy4
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
228M150M75M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
576M380M190M0
Revenue to Profit
2025$189.8M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-196.5M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

The Motley Fool
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
NeutralRYTMAugust 23, 2026
The Motley FoolNeutral
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
RYTM

MarketBeat
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
NeutralRYTMAugust 17, 2026
MarketBeatNeutral
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
RYTM

MarketBeat
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
NeutralRYTMAugust 4, 2026
MarketBeatNeutral
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
RYTM

Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
NeutralRYTMAugust 4, 2026
Zacks Investment ResearchNeutral
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
RYTM

Reuters
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
NeutralRYTMAugust 4, 2026
ReutersNeutral
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
RYTM

Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NeutralRYTMJuly 28, 2026
Zacks Investment ResearchNeutral
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
RYTM

Proactive Investors
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
NeutralRYTMJune 16, 2026
Proactive InvestorsNeutral
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
RYTM

Investors Business Daily
The Battle Against Genetic Obesity Just Sent This Biotech Stock Flying
NeutralRYTMJune 15, 2026
Investors Business DailyNeutral
The Battle Against Genetic Obesity Just Sent This Biotech Stock Flying
RYTM

Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
NeutralRYTMMay 5, 2026
Zacks Investment ResearchNeutral
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates
RYTM

Zacks Investment Research
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for
NeutralRYTMApril 28, 2026
Zacks Investment ResearchNeutral
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for
RYTM
About Rhythm Pharmaceuticals, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees414
CEODr. David P. Meeker M.D.
IPO DateOct 5, 2017
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. David P. Meeker M.D. | Chairman, President & CEO | 1954 |
| Mr. Hunter C. Smith M.B.A. | CFO & Treasurer | 1969 |
| Dr. Alastair Garfield Ph.D. | Chief Scientific Officer | 1980 |
| Mr. Yann Mazabraud | Executive VP & Head of International | 1973 |
| Ms. Jennifer Lee | Executive VP & Head of North America | 1975 |
| Mr. Christopher P. German | Corporate Controller & Principal Accounting Officer | 1972 |
| Mr. Joseph Shulman | Chief Technical Officer | 1975 |
| Mr. David Connolly | Head of Investor Relations & Corporate Communications | — |
| Mr. Jim Flaherty | Senior VP & General Counsel | — |
| Ms. Sarah Ryan | Vice President of Sales & Marketing | — |
Fundamentals
Valuation
Market cap$6.79B
Price-to-sales ratio28.21
Price-to-book value65.73
Price-earnings ratio-32.20
Return on Equity-208.00%
Return on Sales-84.00%
Return on Assets-46.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.11
Income Statement
Average volume575,626
EBITDA$-180.75M
1 year high (52w)$122.20
1 year low (52w)$74.50
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
5 Wall Street Analyst Ratings
BUY
80% Buy
20% Hold
0% Sell
Target price
$144.80
Est return
46.83%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.0 | -12.1 | -26.0 | +15.8 | ||||||||
| 2022 | -30.6 | -0.5 | +35.7 | -46.9 | -45.4 | +23.1 | +193.0 | +81.5 | -3.3 | +6.2 | +2.3 | +7.9 |
| 2023 | -4.5 | -11.1 | -31.0 | +8.4 | -17.6 | -4.0 | +10.6 | +14.3 | -17.5 | +4.6 | +39.3 | +36.0 |
| 2024 | -2.3 | -6.3 | -0.9 | -6.8 | -13.9 | +8.5 | +13.0 | +1.0 | +14.0 | -7.8 | +26.6 | -8.0 |
| 2025 | -1.1 | -7.6 | +1.1 | +30.4 | -3.9 | -0.7 | +30.2 | +16.8 | -3.1 | +13.7 | -4.1 | +1.9 |
| 2026 | -2.4 | -14.9 | -8.4 | -7.7 | +8.0 | +26.4 | -10.1 | +3.3 | -5.8 |



